Boston Scientific Corporation Overview
Pro stress-test →Boston Scientific is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company generated net sales of $20.074 billion in 2025, growing 19.9 percent on a reported basis.
Strategic Profile
Pro stress-test →Boston Scientific is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. In January 2026, Boston Scientific announced it would acquire Penumbra in a ~$15 billion cash and stock deal expected to close by yearend. The company is pursuing aggressive M&A to expand its interventional medical device portfolio and strengthen market position in high-growth segments.
Competitive Landscape
Pro stress-test →Boston Scientific competes against major diversified medical device manufacturers including Medtronic, Stryker, and Johnson & Johnson's Cardiovascular/Specialty Solutions division. The company maintains competitive advantages through proprietary drug-eluting stent technology, expansive interventional device portfolio, and strategic M&A that accelerates entry into adjacent high-growth markets.
Industry Context
Boston Scientific Corporation operates in Medical Devices & Equipment Manufacturing.
Key facts
Founded: 1979 · Headquarters: Marlborough, Massachusetts, US · Employees: 31,000 · Revenue: $20.1B · Market cap: $110B